James O. McNamara

James O. McNamara

Auto-generated profile, based on publicly available information

James O. McNamara

Nuclease Probe Technologies, Inc

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2006 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
JMJames O McNamara
James O McNamara
EAEran R Andrechek
Eran R Andrechek
YWYong Wang
Yong Wang
KVKristi D Viles
Kristi D Viles
RRRachel E Rempel
Rachel E Rempel
PGPaloma H Giangrande
Paloma H Giangrande

23 August 2009 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
JDJustin P Dassie
Justin P Dassie
XLXiu-Ying Liu
Xiu-Ying Liu
GTGregory S Thomas
Gregory S Thomas
RWRyan M Whitaker
Ryan M Whitaker
KTKristina W Thiel
Kristina W Thiel
PGPaloma Giangrande
Paloma Giangrande

2 January 2008 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
JMJames O. McNamara
James O. McNamara
DKDespina Kolonias
Despina Kolonias
Fernando PastorFernando Pastor
Fernando Pastor
RMRobert S. Mittler
Robert S. Mittler
LCLieping Chen
Lieping Chen
EGEli Gilboa
Eli Gilboa
4-1BB is a major costimulatory receptor that promotes the survival and expansion of activated T cells. Administration of agonistic anti–4-1BB Abs has been previously shown to enhance tumor immunity in mice. Abs are cell-based products posing significant cost, manufacturing, and regulatory challenges. Aptamers are oligonucleotide-based ligands that exhibit specificity and avidity comparable to, or exceeding, that of Abs. To date, various aptamers have been shown to inhibit the function of their cognate target. Here, we have described the development of an aptamer that binds 4-1BB expressed on the surface of activated mouse T cells and shown that multivalent configurations of the aptamer costimulated T cell activation in vitro and mediated tumor rejection in mice. Because aptamers can be chemically synthesized, manufacturing and the regulatory approval process should be substantially simpler and less costly than for Abs. Agonistic aptamers could therefore represent a superior alternative to Abs for the therapeutic manipulation of the immune system.

30 March 2012 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
KTKristina W. Thiel
Kristina W. Thiel
LHLuiza I. Hernandez
Luiza I. Hernandez
JDJustin P. Dassie
Justin P. Dassie
WTWilliam H. Thiel
William H. Thiel
XLXiuying Liu
Xiuying Liu
PGPaloma Giangrande
Paloma Giangrande
Human epidermal growth factor receptor 2 (HER2) expression in breast cancer is associated with an aggressive phenotype and poor prognosis, making it an appealing therapeutic target. Trastuzumab, an HER2 antibody-based inhibitor, is currently the leading targeted treatment for HER2+-breast cancers. Unfortunately, many patients inevitably develop resistance to the therapy, highlighting the need for alternative targeted therapeutic options. In this study, we used a novel, cell-based selection approach for isolating ‘cell-type specific’, ‘cell-internalizing RNA ligands (aptamers)’ capable of delivering therapeutic small interfering RNAs (siRNAs) to HER2-expressing breast cancer cells. RNA aptamers with the greatest specificity and internalization potential were covalently linked to siRNAs targeting the anti-apoptotic gene, Bcl-2. We demonstrate that, when applied to cells, the HER2 aptamer-Bcl-2 siRNA conjugates selectively internalize into HER2+-cells and silence Bcl-2 gene expression. Importantly, Bcl-2 silencing sensitizes these cells to chemotherapy (cisplatin) suggesting a potential new therapeutic approach for treating breast cancers with HER2+-status. In summary, we describe a novel cell-based selection methodology that enables the identification of cell-internalizing RNA aptamers for targeting therapeutic siRNAs to HER2-expressing breast cancer cells. The future refinement of this technology may promote the widespread use of RNA-based reagents for targeted therapeutic applications.

1 October 2011 in Nucleic Acid Therapeutics
Verified
Journal Article
Closed access
WRWilliam M. Rockey
William M. Rockey
FHFrank J. Hernandez
Frank J. Hernandez
SHSheng-You Huang
Sheng-You Huang
SCSong Cao
Song Cao
CHCraig A. Howell
Craig A. Howell
PGPaloma Giangrande
Paloma Giangrande
RNA aptamers represent an emerging class of pharmaceuticals with great potential for targeted cancer diagnostics and therapy. Several RNA aptamers that bind cancer cell-surface antigens with high affinity and specificity have been described. However, their clinical potential has yet to be realized. A significant obstacle to the clinical adoption of RNA aptamers is the high cost of manufacturing long RNA sequences through chemical synthesis. Therapeutic aptamers are often truncated postselection by using a trial-and-error process, which is time consuming and inefficient. Here, we used a “ rational truncation ” approach guided by RNA structural prediction and protein/RNA docking algorithms that enabled us to substantially truncateA9, an RNA aptamer to prostate-specific membrane antigen (PSMA),with great potential for targeted therapeutics. This truncated PSMA aptamer (A9L; 41mer) retains binding activity, functionality, and is amenable to large-scale chemical synthesis for future clinical applications. In addition, the modeled RNA tertiary structure and protein/RNA docking predictions revealed key nucleotides within the aptamer critical for binding to PSMA and inhibiting its enzymatic activity. Finally, this work highlights the utility of existing RNA structural prediction and protein docking techniques that may be generally applicable to developing RNA aptamers optimized for therapeutic use.

1 October 2011 in Molecular Therapy
Verified
Journal Article
Open access
Fernando PastorFernando Pastor
Fernando Pastor
DKDespina Kolonias
Despina Kolonias
JIJames O McNamara II
James O McNamara II
EGEli Gilboa
Eli Gilboa
The paucity of costimulation at the tumor site compromises the ability of tumor-specific T cells to eliminate the tumor. Here, we show that bi-specific oligonucleotide aptamer conjugates can deliver costimulatory ligands to tumor cells in situ and enhance antitumor immunity. In poorly immunogenic subcutaneously implanted tumor and lung metastasis models, systemic delivery of an agonistic 4-1BB aptamer ligand conjugated to a prostate specific membrane antigen (PSMA)-binding tumor-targeting aptamer led to inhibition of tumor growth, was more effective than, and synergized with, vaccination, and exhibited a superior therapeutic index compared to costimulation with 4-1BB antibodies. Tumor inhibition was dependent on homing to PSMA-expressing tumor cells and 4-1BB costimulation. Aptamer targeted costimulation is a broadly applicable and clinically feasible approach to enhance the costimulatory environment of disseminated tumor lesions. This study suggests that potentiating naturally occurring antitumor immunity via tumor-targeted costimulation could be an effective approach to elicit protective immunity to control tumor progression in cancer patients.